![Mark Bachleda](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Bachleda
Direktor/Vorstandsmitglied bei
LYELL IMMUNOPHARMA, INC.
Vermögen: - $ am 30.09.2026
Profil
Mark J.
Bachleda is currently Chief Executive Officer & Director at Eyconis, Inc. since 2024 and Independent Director at Lyell Immunopharma, Inc. starting in 2025.
Former positions include Vice President at Bristol Myers Squibb Co., Chief Commercial Officer at Galera Therapeutics, Inc. from 2021 to 2023, and Vice President-Sales & Account Management at Juno Therapeutics, Inc. Education includes an MBA from the University of California, Berkeley and a doctorate from the University of Illinois.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 10.06.2026 | 0 ( -.--% ) | - $ | 30.09.2026 |
Aktive Positionen von Mark Bachleda
| Unternehmen | Position | Beginn |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Direktor/Vorstandsmitglied | 09.06.2025 |
Ehemalige bekannte Positionen von Mark Bachleda
| Unternehmen | Position | Ende |
|---|---|---|
| GALERA T COM USD0. | Corporate Officer/Principal | 09.08.2023 |
| JUNO THERAPEUTICS INC | Vertrieb & Marketing | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Ausbildung von Mark Bachleda
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
23
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Galera Therapeutics, Inc.
 Galera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs to reduce normal tissue toxicity from radiotherapy | Health Technology |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois
 University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company to treat cancer, HIV and cardiovascular diseases | Health Technology |
Lyell Immunopharma, Inc.
 Lyell Immunopharma, Inc. BiotechnologyHealth Technology Develops cell-based immunotherapies for human diseases | Health Technology |
